Orchestra BioMed Holdings Inc. (OBIO) — Cash Flow-to-Debt Ratio
Orchestra BioMed Holdings Inc. (OBIO) has a Cash Flow-to-Debt Ratio of -0.24x as of September 2025, meaning its operating cash flow of $-14.55 Million could theoretically repay 0% of its total liabilities ($61.07 Million) in one year. See Orchestra BioMed Holdings Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Orchestra BioMed Holdings Inc. Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Orchestra BioMed Holdings Inc. across 5 annual periods. Also explore Orchestra BioMed Holdings Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Orchestra BioMed Holdings Inc. (2020–2024)
Year-by-year debt coverage analysis for Orchestra BioMed Holdings Inc.. For market capitalisation and broader financial context, see Orchestra BioMed Holdings Inc. (OBIO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.17x | $-50.56 Million | $43.22 Million | ▲ +31.1% |
| 2023 | -1.70x | $-46.13 Million | $27.17 Million | ▼ -149.5% |
| 2022 | -0.68x | $-29.29 Million | $43.04 Million | ▼ -196.9% |
| 2021 | -0.23x | $-19.43 Million | $84.76 Million | ▲ +24.2% |
| 2020 | -0.30x | $-26.18 Million | $86.63 Million | — |